Sun, X. et al. Sci. Transl. Med. 11, eaau7531 (2019)
Although evidence suggests that cystic fibrosis (CF) — a multiorgan disease caused by mutations in the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR) — starts in utero, the long-term effects of in utero abnormalities on the pathology of CF remain unclear. VX-770 (ivacaftor) is a CFTR potentiator that rescues channel gating in dysfunctional CTFR proteins from patients carrying a CFTRG551D mutation. The results of a new study showing that in utero administration of VX-770 in CFTRG551D ferrets protects the animals from developmental abnormalities and neonatal mortalilty associated with CF suggest that early interventions could improve the treatment of CF. The study also offers a new model to understand the role of CFTR in CF pathophysiology and inform future therapies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Le Bras, A. Cystic fibrosis in ferrets. Lab Anim 48, 165 (2019). https://doi.org/10.1038/s41684-019-0322-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41684-019-0322-x